In the past week, BEAM stock has gone up by 18.49%, with a monthly gain of 18.56% and a quarterly surge of 31.99%. The volatility ratio for the week is 7.82%, and the volatility levels for the last 30 days are 6.39% for Beam Therapeutics Inc The simple moving average for the last 20 days is 13.87% for BEAM stock, with a simple moving average of -12.51% for the last 200 days.
Is It Worth Investing in Beam Therapeutics Inc (NASDAQ: BEAM) Right Now?
Moreover, the 36-month beta value for BEAM is 2.21. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 4 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BEAM is 89.78M and currently, short sellers hold a 24.21% of that float. On July 08, 2025, BEAM’s average trading volume was 2.08M shares.
BEAM) stock’s latest price update
Beam Therapeutics Inc (NASDAQ: BEAM) has seen a rise in its stock price by 5.08% in relation to its previous close of $19.18. However, the company has experienced a 18.49% gain in its stock price over the last five trading sessions. fool.com reported 2025-06-28 that There’s a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving.
Analysts’ Opinion of BEAM
Many brokerage firms have already submitted their reports for BEAM stocks, with BofA Securities repeating the rating for BEAM by listing it as a “Buy.” The predicted price for BEAM in the upcoming period, according to BofA Securities is $42 based on the research report published on March 28, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see BEAM reach a price target of $40. The rating they have provided for BEAM stocks is “Sector Outperform” according to the report published on March 10th, 2025.
BEAM Trading at 13.62% from the 50-Day Moving Average
After a stumble in the market that brought BEAM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.82% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BEAM starting from Simon Amy, who sale 876 shares at the price of $20.12 back on Jul 03 ’25. After this action, Simon Amy now owns 64,864 shares of Beam Therapeutics Inc, valued at $17,625 using the latest closing price.
Simon Amy, the Chief Medical Officer of Beam Therapeutics Inc, sale 374 shares at $16.94 during a trade that took place back on Jul 01 ’25, which means that Simon Amy is holding 65,740 shares at $6,336 based on the most recent closing price.
Stock Fundamentals for BEAM
Current profitability levels for the company are sitting at:
- -6.77 for the present operating margin
- 0.74 for the gross margin
The net margin for Beam Therapeutics Inc stands at -6.09. The total capital return value is set at -0.32. Equity return is now at value -38.04, with -27.41 for asset returns.
Based on Beam Therapeutics Inc (BEAM), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -2.22. The debt to equity ratio resting at 0.14. The interest coverage ratio of the stock is -30.35.
Currently, EBITDA for the company is -383.98 million with net debt to EBITDA at 0.93. When we switch over and look at the enterprise to sales, we see a ratio of 26.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.81.
Conclusion
To wrap up, the performance of Beam Therapeutics Inc (BEAM) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
